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Abstract
Objectives This review surveys current pharmacotherapies available for the
treatment of diabetic peripheral neuropathy (DPN), emphasising their mecha-
nisms of action.
Methods A comprehensive literature review focusing on the ‘pharmacotherapy
and treatment of diabetic peripheral neuropathy’ was conducted. The Database
of International Pharmaceutical Abstracts, EMBASE, PubMed, OVID, Scopus,
Google and Google Scholar were searched, and reference lists of relevant articles
were also included.
Key findings Diabetic peripheral neuropathy is often inadequately treated, and
the role of improving glycaemic control specifically in type-2 diabetes remains
unclear. It is crucial to explore the mechanisms of action and effectiveness of
available therapies. Major international clinical guidelines for the management of
DPN recommend several symptomatic treatments. First-line therapies include
tricyclic antidepressants, serotonin–noradrenaline reuptake inhibitors, and anti-
convulsants that act on calcium channels. Other therapies include opioids and
topical agents such as capsaicin and lidocaine. The objectives of this paper are to
review current guidelines for the pharmacological management of DPN and to
discuss research relevant to the further development of pharmacological recom-
mendations for the treatment of diabetic neuropathy.
Summary Diabetic neuropathy is a highly prevalent, disabling condition, the
management of which is associated with significant costs. Evidence supports the
use of specific anticonvulsants and antidepressants for pain management in
patients with diabetic peripheral neuropathy. All current guidelines advise a per-
sonalised approach with a low-dose start that is tailored to the maximum
response having the least side effects or adverse events.
Introduction
Diabetes has become an epidemic problem in the 21st cen-
tury. According to the International Diabetes Federation,
the global population of diabetes patients is predicted to
reach a pandemic level of 366 million by 2030, double the
number from 2000.[1] Diabetic peripheral neuropathy
(DPN) is the most common diabetic complication, the
most common form of neuropathy, and the leading cause
of disability, foot ulceration and ultimately amputation.
Furthermore, twenty to thirty per cent of DPN patients suf-
fer neuropathic pain,[2–4] which is often chronic, severe and
difficult to treat and manage. This pain negatively affects
quality of life and poses a significant burden, increasing
associated health costs. It has been estimated that the total
yearly per-patient cost of diabetes is $6632[5]; the cost is
twofold greater for those with peripheral neuropathy, and
fourfold for those with moderate to severe pain.[5] Patients
with DPN also score higher for the experience of anxiety,
depression and sleep disturbances.[6,7]
The major sign and symptom of DPN is symmetrical
sensory pain affecting the lower limbs.[8] Other presenta-
tions include atypical pain, numbness, pins and needles,
and hot or burning sensations.[9] It can also feature other
presentations of nerve motor dysfunction, such as muscle
weakness, poor balance and propensity to fall.
Treatment of DPN is challenging, and effective therapies
are not available for many patients; therefore, developing
improved pharmacotherapy and guidelines are essential. In
the last twenty years, a number of professional associations
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have published many different international clinical prac-
tices; these help physicians choose appropriate pharma-
cotherapy plans for the management of DPN.[10] There is a
limited literature with regard to pharmacological and com-
bination treatment to prevent or reverse DPN changes or
to provide total pain relief. There are a number of unmet
needs in the therapeutic management of painful DPN.
These include the need for randomised controlled trials
with active comparators and data on the long-term efficacy
of agents used. Finally, there is a need for appropriately
designed studies to investigate non-pharmacological
approaches.
This paper will discuss pharmacotherapy approaches
based on a literature review of existing studies, guidelines
and clinical practices for the treatment of diabetic neuropa-
thy.
Methods
A comprehensive literature review focusing on the ‘phar-
macotherapy and treatment of diabetic peripheral neuropa-
thy’ was conducted. The Database of International
Pharmaceutical Abstracts, EMBASE, PubMed, OVID, Sco-
pus, Google and Google Scholar were searched, and refer-
ence lists of relevant articles were included.
Search strategy and inclusion criteria
The key words used were ‘diabetic neuropathy’, ‘DPN’,
‘Diabetes Guideline’, ‘diabetic complications’, ‘Drugs’,
‘pharmacotherapy’, ‘pharmaceuticals’, combined with
‘drugs’ and ‘medicines.’ The term ‘DPN’ was also searched
in combination with ‘Opioids, Pregabalin, Serotonin–nora-
drenaline reuptake inhibitors, Tricyclic antidepressants’
and ‘gabapentin, duloxetine, tramadol, opioids, lidocaine
patch, and capsaicin patch’. Additional journal articles not
found through searching the above databases were individ-
ually retrieved. The websites of relevant organisations, such
as the WHO, were also consulted for research articles. The
search was limited to the period from January 1990 to
December 2019. Articles that the author considered not rel-
evant were excluded from the review.
Out of the initial return of 613 articles, 56 were chosen
for further screening and analysis. The final analysis con-
sisted of 93 articles (Figure 1).
Results and discussion
Pathophysiology of DPN
The pathogenesis of DNP is not fully understood. Several
theories have been proposed to explain the pain related to
the diabetic neuropathy. Diabetic peripheral neuropathy is
characterised by diffuse damage to the peripheral nerve
fibres. About 30–90% of patients with diabetes have
peripheral neuropathy. Diabetic sensorimotor polyneu-
ropathy (DSPN), the most common type of diabetic neu-
ropathy, is associated with pain, an impaired quality of life,
significant morbidity and increased healthcare costs.[11] An
increased free-radical production along with defective
antioxidant mechanisms can generate oxidative stress that
has been linked to the development of DSPN. Other theo-
ries suggested changes in the blood vessels that supply the
peripheral nerves; metabolic and autoimmune disorders
accompanied by glial cell activation, changes in sodium
and calcium channel expression and more recently, central
pain mechanisms, such as increased thalamic vascularity
and imbalance of the facilitatory/inhibitory descending
pathways.[11,12] Additionally, several risk factors are associ-
ated with DNP including worsening glucose tolerance,
older age, longer diabetes duration, drinking alcohol and
cigarette smoking.
Approach considerations
Almost 90% of diabetic foot ulcers can be attributed in a
whole or in part to diabetic neuropathy. Any patient with
clinical evidence of DPN should be considered at risk for
foot ulceration and educated regarding foot care.[13] Ulcer
occurrence can be decreased by 50%, and the need for
major amputation in non-ischaemic limbs eliminated, by
patient education, simple hygienic practices, provision of
Figure 1 Schematic diagram elaborating the selection of stud-
ies/documents.
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appropriate footwear, regular foot examination and the
prompt treatment of minor injuries.[14,15]
Glycaemic control
The Diabetes Controls and Complications Trial (DCCT)
demonstrated that tight control of blood glucose in patients
with type-1 diabetes reduces the risk of DPN by 60%.[16]
The same is not the case for type-2 diabetes; several studies
have demonstrated that aggressive glycaemic control has no
meaningful impact on patient risk for polyneuropa-
thy.[17,18] A systemic review by Callaghan et al. did indicate
that glycaemic control prevents the development of
polyneuropathy in patients with either type of diabetes.
However, tight control also increased the risk of adverse
events, namely hypoglycaemic episodes.[19] Another meta-
analysis of randomised control studies by Boussageon et al.
indicated no significant benefit from intensive glycaemic
control in terms of reducing DPN in patients with type-2
diabetes.[20]
Relieving pain
Peripheral neuropathy is the most common type of diabetic
neuropathic pain, and its most common sign and symptom
is moderate to severe pain.[11,21] International guidelines
issued by the American Academy of Neurology (AAN),
European Federation of Neurological Societies (EFNS),
Neuropathic Pain Special Interest Group of the Interna-
tional Association for the Study of Pain (NeuPSIG IASP)
and the National Institute for Health and Care Excellence
(NICE) all agree that the first-line medications for treat-
ment are calcium channel a2-d ligands (gabapentin and
pregabalin) and antidepressants that inhibit reuptake of
both serotonin and noradrenaline.[12] Some patients may
benefit from opioids or topical therapy with capsaicin or
transdermal lidocaine (Table 1).
First-line therapy
Tricyclic antidepressants and selective serotonin and nora-
drenaline reuptake inhibitors. Tricyclic antidepressants
(TCAs) include imipramine and amitriptyline (tertiary
amines) along with desipramine and nortriptyline (sec-
ondary amines). These block the reuptake of noradrenaline
and serotonin by the presynaptic neuron. Another pro-
posed mechanism of action that may contribute to their
analgesic effect is blocking the uptake of both 5HT and
noradrenaline; meanwhile, their adverse effects likely result
from actions on histaminic and muscarinic receptors. Con-
trol studies have consistently supported the efficacy of
TCAs in treating painful DPN.[22,23] Tricyclic antidepres-
sants are well-absorbed via oral administration, and their
lipophilic nature allows them to be widely distributed and
to readily penetrate into the central nervous system (CNS).
However, they have inconsistent, low bioavailability due to
variable first-pass metabolism in the liver, and require up-
titration to effective doses, often over a period of 6–
8 weeks.[24–27] Side effects include dry mouth, orthostatic
hypotension, constipation and urinary retention. More-
over, TCAs are contraindicated in patients with glaucoma,
prostate hypertrophy or certain cardiac conduction distur-
bances.[28,29] Secondary amines are better tolerated than
tertiary amines.[30–32]
Serotonin and noradrenaline reuptake inhibitors. Simulta-
neous inhibition of noradrenaline and serotonin reuptake
can relieve pain associated with DPN, postherpetic neural-
gia, fibromyalgia and lower back pain.[33] We identified 13
studies that demonstrated the effects of serotonin and nora-
drenaline reuptake inhibitors (SNRIs) in treating DPN.
Duloxetine was the most studied SNRI, with eight ran-
domised controlled trials (RCTs) showing a positive effect
for duloxetine compared with placebo.[34–42] A meta-analy-
sis review revealed that duloxetine (60 mg) was signifi-
cantly more effective than placebo, with a pain reduction of
50% and a NNT of 5 (Table 2).[39] In an open-label, ran-
domised, non-inferiority comparison, duloxetine showed
the same efficacy as pregabalin in treating patients with
painful DPN.[40] Relative to TCAs, duloxetine has fewer
and more favourable side effects due to having less effect
on cholinergic and histaminic receptors; constipation was
reported in one study.[41] Due to its efficacy, safety profile
and cost-effectiveness,[42] duloxetine was endorsed in the
2013 NICE guidelines (Table 1).
Venlafaxine is a potent inhibitor of serotonin reuptake; it
also inhibits noradrenaline reuptake at medium to high
doses. Review studies revealed that venlafaxine at 150–
225 mg/day is significantly more effective than placebo,
with a 50% reduction in pain (NNT = 3.6).[43,44] Venlafax-
ine takes 2–4 weeks for effective treatment (Table 2), and
when coming off treatment, patients should taper the dose
gradually to prevent the risk of adverse events.[45] Nausea,
headache and insomnia are its most common side effects,
although increased blood pressure and heart rate have been
reported at high doses.[46] It is worth noting that venlafax-
ine does not have FDA approval for treating DPN. A posi-
tive effect of venlafaxine’s major metabolite, desvenlafaxine,
on DPN has been reported by one RCT at doses of 200–
400 mg/day, with good tolerability in both short and long
terms.[47]
Calcium channel a2-d ligands. Gabapentin and pregabalin
both act on the a2-d l subunit of the presynaptic Ca++
channel through the same mechanism[48]; the result is to
decrease the release of neurotransmitters, mainly glutamate
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and noradrenaline and to some extent substance P.[49] Sev-
eral studies have shown a significant effect for gapabentin
in reducing DPN, and some that it moreover improved
sleep, mood and quality of life.[50–56] Doses used ranged
from 900 to 3600 mg/day; the efficacy may decrease with
decreasing dose, and the NNT to achieve 50% pain
Table 1 Selected guideline recommendations for drugs used for pain in diabetic neuropathy
Drug NNT AAN NICE EFNS
NeuPSIG
IASP Mechanism of action
GABA analogues Fist line Fist line
Pregabalin 5.0 First line First line Bind to voltage-gated calcium
channels and reduces the synaptic
release of several neurotransmitters
Gabapentin 6.0 First line
TCAs First line
Amitriptyline 1.3 Second line First line Inhibit reuptake of noradrenaline
and serotonin
Imipramine 2.2 Second line First line
Desipramine 2.6 First line
SNRIs Second line First line First line
Duloxetine 5.0 First line Inhibit reuptake of noradrenaline
and serotonin augmenting
descending inhibitory pathways
Venlafaxine 3.1
Opioids Second line Second line Second line
Strong opioids 4.1 Second line
Tramadol 4.4 Second line Second line Partial l-receptor Agonists weak
opioid and inhibits noradrenaline
and serotonin reuptake
Topical
Capsaicin
(0.075% cream)
6.6 Second line By depleting substance P at vanilloid
nerve
Lidocaine 5% patch 4.0 Second line Second line Local anaesthetic
AAN, American Academy of Neurology; EFNS, European Federation of Neurological Societies; IENFD, intraepidermal nerve fibre density; NeuPSIG
IASP, Neuropathic Pain Special Interest Group of the International Association for the Study of Pain; NICE, National Institute for Health and Care
Excellence; NNT, Number Needed to Treat for at least 50% pain relief. Adapted Ref. [11].
Table 2 Recommended doses of drugs or drug classes with strong or weak recommendationsa
Total daily dose and dose regimen Recommendations
Strong recommendations for use
Gapabentin 1200–3600 mg, in three divided doses First line, adequate trial 3–8 weeks
Gabapentin extended release 1200–3600 mg, in two divided doses First line, adequate trial 3–8 weeks
Pregabalin 300–600 mg, in two divided doses First line, adequate trial 6–8 weeks
Serotonin-noradrenaline reuptake
inhibitors duloxetine or venlafaxineb
60–120 mg, once a day (duloxetine); 150–225 mg,
once a day (venlafaxine extended release)
First line, adequate trial 4–6 weeks
Tricyclic antidepressantsa 25–150 mg, once a day or in two divided doses First line, adequate trial 6–8 weeks
Weak recommendations for use
Capsaicin 8% patches One to four patches to the painful area
for 30–60 min every 3 months
Second line (peripheral neuropathic pain)
Lidocaine patches One to three patches to the region of
pain once a day for up to 12 h
Second line (peripheral neuropathic pain),
adequate trial 3 weeks
Tramadol 200–400 mg, in two (tramadol extended release)
or three divided doses
Botulinum toxin A (subcutaneously) 50–200 units to the painful area every 3 months Third line; specialist use
(peripheral neuropathic pain)
Strong opioids Individual titration Third line, adequate trial 4–6 weeks
aConsider lower starting dosages and slower titration in geriatric patients. bDuloxetine is the most studied, and therefore recommended, of the
serotonin–noradrenaline reuptake inhibitors.
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reduction was calculated to be 6 (Table 2). Due to the non-
linear kinetics of gabapentin, the dose should be gradually
increased until reaching 1800–3600 mg/day in divided
doses and should be reduced in renal disease. Gabapentin is
well-tolerated by the elderly because of its relatively mild
adverse effects and possibly also due to having few drug
interactions.[24]
Pregabalin is a more potent calcium channel a2-d
ligand approved by the FDA for treating DPN. Its
efficacy has been demonstrated in several randomised
studies,[57–61] and one meta-analysis comparing number
of drugs found pregabalin to be the most efficacious
agent.[62] Pregabalin produces a dose-dependent response
in terms of reduced anxiety, reduced sleep disorders and
improved quality of life, and the speed of onset of pain
relief make it more favourable in patients with chronic
pain.[63–66] An initial dose of 150 mg/day is recom-
mended, particularly for older patients; however, it may
be gradually increased to achieve maximum benefit at
300–600 mg/day. The NNT to achieve 50% pain reduc-
tion was calculated to be 5 (Table 2).[11]
Second-line therapy
Opioid analgesics. Opioid analgesics can be used as first-
line therapy in selected clinical situations.[8] However, due
to their safety profile and potential for abuse, many guideli-
nes consider opioids as second- or more recently as third-
line therapies (Table 1).[26] Several studies have demon-
strated positive effects of strong opioids in the management
of peripheral neuropathy.[67–73] Oxycodone, morphine and
methadone are the strongest opioids used in treating neu-
ropathic pain.[74] A Cochrane review by McNicol et al.[75]
additionally evaluated strong opioids in treating neuro-
pathic pain and revealed significant pain reduction com-
pared with placebo; however, the studies used were of short
duration (<2 weeks), and the risk of opioid misuse or
abuse has not been evaluated for patients with chronic neu-
ropathy. Oxycodone dosages range from 10 to 120 mg/day,
and morphine from 90 to 240 mg/day with maximum ben-
efit at 180 mg/day; the NNT was 4.1.[26] Further studies are
needed to evaluate the long-term risk of chronic opioid use
in the management of neuropathic pain.
Tramadol. Tramadol is a partial l-receptor agonist and a
weak opioid that inhibits noradrenaline and serotonin
reuptake. Most international guidelines consider tramadol
to be a second-line therapy, reserved for those who did not
respond to or experienced withdrawal symptoms from
first-line therapy.[76–80] Harati et al.[78] used a double-
blind randomised trial to evaluate the efficacy and safety
of tramadol as a treatment for DPN pain. They found
that a dose of 210 mg/day was more significant and
effective than placebo in relieving DPN pain (P < 0.001).
A Cochrane review that assessed the efficacy of tramadol
considered results from six RCTs and found tramadol to
be effective at doses of 200–400 mg/day with a calculated
NNT of 4.4 (95% CI: 2.9–8.8). However, not all studies
reported all outcomes; therefore, data regarding the effi-
cacy of tramadol in neuropathic pain is limited.[81] Its
most common adverse effects are constipation, nausea,
somnolence, dizziness and orthostatic hypotension. Doses
should be reduced in elderly patients and in patients
with hepatic or renal impairment.
Third-line therapy
Topical medications. Chilli pepper (Capsicum) extracts
have long been used as rubefacients in the treatment of
painful disorders. Capsaicin is an alkaloid derived from red
chilli peppers. Pharmacologically, it works by depleting
substance P at vanilloid nerve receptors, which causes a
reduction in the conveyance of painful stimuli to the
CNS.[82] The Capsaicin Study Group undertook a RCT to
assess the efficacy of topical capsaicin cream (0.075%) in
relieving DPN-associated pain.[83] They observed signifi-
cant enhancement in pain relief compared with placebo
(58.4% vs 45.3%). The most common side effects were
transient burning, sneezing and coughing.
Lidocaine. Lidocaine patches 5% work as peripheral anal-
gesics; lidocaine has low systemic absorption and is used in
combination with other analgesic drugs.[84] Very few stud-
ies comparing topical lidocaine with other agents exist
(Table 3). One study showed pain relief comparable to pre-
gabalin (55% vs 66%); however, more enhancement in
quality of life was observed in the lidocaine group.[85]
Other treatments
Alpha lipoic acid. Alpha lipoic acid (ALA) is an antioxidant
agent that has been studied for the treatment of DPN. It
directly relieves pain by reducing oxidative stress, which is
an important mechanism in the pathogenesis of DPN
pain.[85] In one RCT assessing the effect of ALA on DPN
pain, patients reported greater improvement than with pla-
cebo.[85] Additionally, a meta-analysis that used 448
patients and a daily intravenous dose of 600 mg for
3 weeks identified greater pain relief through one year of
follow-up.[86] Relative to other DPN treatments, ALA has
fewer adverse effects (mainly nausea and vomiting).
Acupuncture. One single RCT to evaluate the effect of
acupuncture in DPN pain reported an enhancement in
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pain relief in 45 subjects, compared with placebo.[87] How-
ever, a systematic review by Chen et al. found that clinical
trials studying the effects of acupuncture lack robust out-
come measures (Table 3). Given this deficit of high-quality
RCTs, acupuncture has not been approved for treatment of
DPN.[88]
Role of the pharmacist
Recently, the role of pharmacists has expanded from
product-oriented to patient-oriented.[89] The inclusion
of pharmacists on an interdisciplinary primary care team
is a promising strategy for improving pain manage-
ment.[90] Pharmacists are the first healthcare provider
patients encounter when inquiring about treatment
options regarding DPN pain. Additionally, pharmacists
are the providers with primary responsibility for safely
and accurately distributing a medication product to a
patient with DPN.[91] It is important for pharmacists to
provide counselling about dosage information, side
effects, and the importance of regular foot examinations.
Furthermore, the importance of regular exercise should
be stressed; in addition to helping improve glucose
control, exercise may prevent not only the progression
but possibly even the onset of DPN.
Conclusion
Pharmacological treatment remains the mainstay for treat-
ing DPN, with pregabalin, gabapentin and SNRIs being
considered first-line therapies. Many pharmacological
options are palliative and do not target the underlying
mechanisms that cause pain. Throughout the large number
of RCTs included in this review, with pharmacological
treatment only moderate pain relief was achieved.
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